Patients With ES-SCLC Are More Likely To Have Durable Chemoimmunotherapy Outcomes If They Have Higher Levels Of Lactotransferrin At Baseline, Research Finds

The American Journal of Managed Care (4/8, Kaltwasser) reports research indicates that “patients with extensive-stage small cell lung cancer (ES-SCLC) are more likely to have durable chemoimmunotherapy outcomes if they have higher levels of lactotransferrin...at baseline.” Investigators came to this conclusion after analyzing “tumor samples from 21 patients with ES-SCLC who were about to undergo treatment.” The findings were published in Cancer Science.